A preclinical study in Cell Death Discovery reports that blocking PHGDH can overcome dabrafenib resistance through metabolic rewiring in BRAF V600E anaplastic thyroid carcinoma models. The work, led by S.Y. Kim and M.H. You, identifies phosphoglycerate dehydrogenase (PHGDH) inhibition as a potential strategy to re-sensitize resistant tumors. PHGDH is part of one-carbon and serine/glycine-associated metabolic pathways that cancer cells can exploit for growth, especially under targeted therapy pressure. In this report, suppressing PHGDH shifted the metabolic dependencies that the tumors developed while resisting dabrafenib. For drug developers pursuing combinations in BRAF-mutant cancers, the results add a candidate metabolic axis that can be evaluated alongside existing targeted therapies. It also highlights the importance of resistance mechanism mapping—particularly for aggressive thyroid cancer variants where durable options remain limited. The next stage for translation will be assessing how broadly the vulnerability applies across resistance mechanisms and whether PHGDH inhibition has manageable tolerability profiles in combination settings.